[{"uuid": "b65bdcce-6595-31ff-bafe-73ad92a7138d", "title": "The 5.4% return this week takes Adaptive Biotechnologies' (NASDAQ:ADPT) shareholders one-year gains to 99%", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/5-4-return-week-takes-143800746.html", "providerPublishTime": 1738161480, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/dC75hPkPk1wNzUHQ29Af1A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/6yvSv34WjsBU70VeapBSyg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ADPT"]}, {"uuid": "ed85f928-62c7-3cec-bfaf-8db8556e25cd", "title": "Why Adaptive Biotechnologies Corporation (ADPT) Is Skyrocketing Now", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/why-adaptive-biotechnologies-corporation-adpt-220649487.html", "providerPublishTime": 1737670009, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/2c97r7d9YLLNG_zGuiBmjg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8b0a71a66a9a4edce4b740c75ecc4cab", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/M3RsD92lx7SicUK2uaN7nw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8b0a71a66a9a4edce4b740c75ecc4cab", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ADPT"]}, {"uuid": "79d5a0ca-2168-3294-b3e5-37db0d0af3df", "title": "Why Is Andreas Halvorsen Bullish On Adaptive Biotechnologies Corporation (ADPT) Now?", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/why-andreas-halvorsen-bullish-adaptive-112113790.html", "providerPublishTime": 1737631273, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/2c97r7d9YLLNG_zGuiBmjg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8b0a71a66a9a4edce4b740c75ecc4cab", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/M3RsD92lx7SicUK2uaN7nw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8b0a71a66a9a4edce4b740c75ecc4cab", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ADPT"]}, {"uuid": "f2e3d9e3-9b34-312e-8e15-45c6463f95e9", "title": "Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/adaptive-biotechnologies-report-fourth-quarter-210500270.html", "providerPublishTime": 1737579900, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/7uMohbVGHxyV_uFltjFKDg--~B/aD0xODQ7dz0zMjc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/8743c1287f8191be5e2b0abdc57e6cc8", "width": 327, "height": 184, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/NlSikA1eF8msjKYwhG70kg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/8743c1287f8191be5e2b0abdc57e6cc8", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ADPT"]}, {"uuid": "3a09cb71-3426-3481-9933-3b9496488038", "title": "Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/adaptive-biotechnologies-adpt-stock-outpacing-144005330.html", "providerPublishTime": 1737124805, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/UYup8AGIrn99rMsHiTllqA--~B/aD04NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee", "width": 900, "height": 876, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/XhCCCM1n.mhdk3ZYrtuYVA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ADPT", "BIO-B"]}, {"uuid": "8a5ca08f-6791-3a69-aaa0-1062d9de68e4", "title": "Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/adaptive-biotechnologies-adpt-soars-18-133300359.html", "providerPublishTime": 1737034380, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/GOd9_vmyYsGT_kCyxDvLhA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1570355885f35f6c0be0cbca2e936d8e", "width": 900, "height": 600, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/995uX4ZXeYoRvv1Vrzqnzw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/1570355885f35f6c0be0cbca2e936d8e", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ADPT", "ACLX"]}, {"uuid": "a6d1d6a5-30ac-30b4-8ea2-b77fc646564a", "title": "Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to\u00a0Personalized Disease Monitoring for Blood Cancer Patients", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/adaptive-biotechnologies-neogenomics-partner-expand-123000512.html", "providerPublishTime": 1736857800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/7uMohbVGHxyV_uFltjFKDg--~B/aD0xODQ7dz0zMjc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/8743c1287f8191be5e2b0abdc57e6cc8", "width": 327, "height": 184, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/NlSikA1eF8msjKYwhG70kg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/8743c1287f8191be5e2b0abdc57e6cc8", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ADPT", "NEO"]}, {"uuid": "5bd838c8-3868-3d0e-a99c-f78dee0610bc", "title": "Adaptive Biotechnologies, NeoGenomics to Support Minimal Residual Disease Monitoring Options for Blood Cancer Patients", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/adaptive-biotechnologies-neogenomics-support-minimal-135944400.html", "providerPublishTime": 1736863184, "type": "STORY", "relatedTickers": ["ADPT", "NEO"]}, {"uuid": "b3b13b38-b56b-3483-b1ee-63cc211bc6f8", "title": "Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ\u00ae Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/adaptive-biotechnologies-announces-clinical-lab-123000676.html", "providerPublishTime": 1736253000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/7uMohbVGHxyV_uFltjFKDg--~B/aD0xODQ7dz0zMjc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/8743c1287f8191be5e2b0abdc57e6cc8", "width": 327, "height": 184, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/NlSikA1eF8msjKYwhG70kg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/8743c1287f8191be5e2b0abdc57e6cc8", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ADPT"]}, {"uuid": "105423fa-4b4c-3ed5-a29c-62a6436bbfe8", "title": "Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/adaptive-biotechnologies-present-43rd-annual-210500820.html", "providerPublishTime": 1735851900, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/7uMohbVGHxyV_uFltjFKDg--~B/aD0xODQ7dz0zMjc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/8743c1287f8191be5e2b0abdc57e6cc8", "width": 327, "height": 184, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/NlSikA1eF8msjKYwhG70kg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/8743c1287f8191be5e2b0abdc57e6cc8", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ADPT"]}, {"uuid": "963a1433-b822-3e77-9c3b-f2bd12cb5957", "title": "Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/ani-pharmaceuticals-anip-outperforming-other-144012134.html", "providerPublishTime": 1735742412, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/26ddEdIk.0DefsBmi91u3Q--~B/aD01OTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177", "width": 900, "height": 598, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Pbek.MpxVnYPyk5tCbA_MQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ANIP", "ADPT"]}, {"uuid": "1044a24b-40c8-3a51-a28c-506c3225172e", "title": "Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/adaptive-biotechnologies-adpt-reports-q3-231506206.html", "providerPublishTime": 1731021306, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/7h8ntzJXcDOdVmDKQ08gRg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a", "width": 900, "height": 600, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Em_DrzACdMhzlbouRNIMyA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ADPT"]}]